Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Epacadostat - Incyte Corporation

Drug Profile

Epacadostat - Incyte Corporation

Alternative Names: INCB-024360; INCB-24360

Latest Information Update: 12 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Incyte Corporation
  • Developer Aduro BioTech; Bristol-Myers Squibb; Columbia University; IMV; Incyte Corporation; MedImmune; Merck AG; Merck Sharp & Dohme; National Cancer Institute (USA); Sidney Kimmel Cancer Center; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Stanford University; Washington University School of Medicine
  • Class Antineoplastics; Oxadiazoles; Small molecules; Sulfonamides
  • Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Urogenital cancer
  • Phase II Fallopian tube cancer; Gastric cancer; Gastrointestinal stromal tumours; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Sarcoma; Solid tumours
  • Phase I/II Cancer; Colorectal cancer; Glioblastoma; Prostate cancer
  • Phase I Rectal cancer

Most Recent Events

  • 10 Oct 2019 Phase-I clinical trials in Rectal cancer (First-line therapy, Neoadjuvant therapy, Late-stage disease) in USA (PO, Tablet) (NCT03516708)
  • 18 Aug 2019 Incyte Corporation terminates phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Combination therapy, Second-line therapy) in USA (PO) (NCT02559492)
  • 04 Jun 2019 Phase I development of epacadostat for ovarian cancer, fallopian tube cancer and peritoneal cancer (Combination therapy, Late-stage disease, Recurrent, Second-line therapy or greater) is ongoing in USA and Canada (PO)(NCT02785250)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top